Published in Cancer Sci on February 09, 2016
Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics (2016) 0.76
A theoretical study on predicted protein targets of apple polyphenols and possible mechanisms of chemoprevention in colorectal cancer. Sci Rep (2016) 0.75
Critical roles of SMYD2-mediated β-catenin methylation for nuclear translocation and activation of Wnt signaling. Oncotarget (2017) 0.75
High-resolution profiling of histone methylations in the human genome. Cell (2007) 85.74
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet (2007) 32.41
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30
Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature (2000) 18.26
Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet (2007) 7.61
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet (2006) 6.65
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol (2004) 4.72
DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol (2008) 4.56
Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics (1998) 4.42
Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J (2007) 3.81
Protein arginine methyltransferases and cancer. Nat Rev Cancer (2012) 2.56
Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer (2011) 2.42
PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation. Genes Dev (2007) 2.34
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet (2005) 2.08
Histone arginine methylation. FEBS Lett (2010) 1.95
Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci (2006) 1.90
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood (2005) 1.81
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer (2011) 1.81
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature (2014) 1.75
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood (2002) 1.65
Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer (2010) 1.64
SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep (2014) 1.57
Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci (2011) 1.57
Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity. Nucleic Acids Res (2013) 1.55
Structural basis of substrate methylation and inhibition of SMYD2. Structure (2011) 1.54
Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis (2009) 1.46
RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia (2012) 1.36
The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers. Mol Cell Biol (2013) 1.35
Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nat Rev Cancer (2015) 1.34
The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res (2007) 1.32
NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov (2014) 1.27
Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B. Nat Commun (2012) 1.27
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol (2015) 1.15
The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells. Neoplasia (2014) 1.09
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia (2011) 1.08
SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation. Cancer Lett (2014) 1.02
The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. Genes Chromosomes Cancer (2012) 1.00
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2. J Biol Chem (2015) 1.00
Critical role of lysine 134 methylation on histone H2AX for γ-H2AX production and DNA repair. Nat Commun (2014) 0.98
The emerging roles of DOT1L in leukemia and normal development. Leukemia (2014) 0.96
The arginine methyltransferase PRMT6 regulates cell proliferation and senescence through transcriptional repression of tumor suppressor genes. Nucleic Acids Res (2012) 0.96
The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination. Neoplasia (2013) 0.93
WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck. Mol Cancer Res (2014) 0.92
DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J Pharmacol Exp Ther (2014) 0.90
NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes. Cancer Genet Cytogenet (2009) 0.87
NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer (2013) 0.86
The NSD family of protein methyltransferases in human cancer. Epigenomics (2015) 0.85
Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2. ACS Med Chem Lett (2015) 0.85
Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS Med Chem Lett (2015) 0.85
A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth. J Cell Physiol (2015) 0.83
SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells. Oncotarget (2015) 0.83
PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents. Oncotarget (2015) 0.83
PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP. Oncotarget (2015) 0.81
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor. ACS Med Chem Lett (2015) 0.81
MMSET: role and therapeutic opportunities in multiple myeloma. Biomed Res Int (2014) 0.80
Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL). Transl Oncol (2015) 0.78
Virtual screening and biological evaluation of novel small molecular inhibitors against protein arginine methyltransferase 1 (PRMT1). Org Biomol Chem (2014) 0.76
A phase ΙI clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci (2016) 0.76
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. J Exp Clin Cancer Res (2017) 0.75